云南白药出手：拟6.6亿元收购聚药堂100%股权

Core Viewpoint - Yunnan Baiyao announced the acquisition of 100% equity in An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for a total consideration of 660 million yuan to enhance its national business layout and scale expansion [1][3] Company Overview - Yunnan Baiyao's market capitalization reached 99.8 billion yuan, with a stock price of 55.96 yuan per share as of August 15 [2] - The target company, Ju Yao Tang, specializes in the production and sales of traditional Chinese medicine (TCM) pieces and has a comprehensive product line with 1,567 types of TCM pieces and 240 registered formula granules [3][4] Financial Performance and Commitments - Ju Yao Tang reported a net profit of 69.33 million yuan for 2024 and 11.49 million yuan for the first quarter of this year [4] - The acquisition includes performance commitments for Ju Yao Tang to achieve main business revenues of 624 million yuan, 616 million yuan, and 666 million yuan from 2025 to 2027, with net profits of 66 million yuan, 59.7 million yuan, and 63.9 million yuan respectively [4] Strategic Implications - The acquisition aligns with Yunnan Baiyao's strategy to expand its market presence outside Yunnan and enhance its product offerings, thereby improving its competitive edge in the industry [6] - Ju Yao Tang's established online sales channels and extensive B2B customer base are expected to provide significant strategic synergies, enhancing the efficiency of Yunnan Baiyao's TCM supply chain [6] Industry Development Goals - The "Three-Year Action Plan for High-Quality Development of Yunnan's Traditional Chinese Medicine Industry (2025-2027)" aims to establish Yunnan Baiyao as the leader in a comprehensive service system for the TCM industry by 2027 [5] - Yunnan Baiyao is committed to integrating traditional medicine into modern life, with a diverse product portfolio of 40 categories and 416 varieties [5]